RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...
Indivior recently released results from a multicenter, open-label clinical trial showing that rapid induction with SUBLOCADE, using a single 4 mg oral buprenorphine dose followed by a same-day ...
RICHMOND - Indivior PLC (NASDAQ:INDV), a pharmaceutical company with a market capitalization of $3.1 billion and an impressive 207% return over the past year, announced Wednesday that a new clinical ...
* SAYS FILED A NEW DRUG SUBMISSION (NDS) WITH HEALTH CANADA'S THERAPEUTIC DRUGS DIRECTORATE FOR SUBLOCADE INJECTION 登録するここ. * SAYS IF APPROVED, SUBLOCADE WILL BE MARKETED BY INDIVIOR CANADA LTD Source ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する